16/03/2017                    
A new class of inhibitors against pain investigated at the ALBA synchrotron
        A new class of inhibitors against pain investigated at the ALBA synchrotron
                                        The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.
Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.
As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.
This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.
                    
                                
                 
            Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.
As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.
This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.
More news
        		        	
            	
                	30/07/2014                 
                Barcelona among the top 10 cities in the world            
                	
            	
                	24/07/2014                 
                Researchers prove the effectiveness of a new drug against malaria using synchrotron light            
                	
            	
                	17/07/2014                 
                Creation of the Health Technologies Cluster             
                	
            	
                	10/07/2014                 
                An international team of scientists led by researchers from the UAB creates the world's first magnetic hose            
                	
            	
                	03/07/2014                 
                CaixaBank and Oracle set up a Big Data Centre of Excellence in the Barcelona Synchrotron Park            
                	
            	
                	26/06/2014                 
                The Barcelona Supercomputing Center hosts two important new international projects            
                    
        
        
        
    
                                    
                            		
                            
                                    
                            		
                            
                                    
                            		
                            
    